BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 9351353)

  • 1. Lovastatin decreases de novo cholesterol synthesis and LDL Apo B-100 production rates in combined-hyperlipidemic males.
    Cuchel M; Schaefer EJ; Millar JS; Jones PJ; Dolnikowski GG; Vergani C; Lichtenstein AH
    Arterioscler Thromb Vasc Biol; 1997 Oct; 17(10):1910-7. PubMed ID: 9351353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologic mechanisms of action of lovastatin in nephrotic syndrome.
    Aguilar-Salinas CA; Barrett PH; Kelber J; Delmez J; Schonfeld G
    J Lipid Res; 1995 Jan; 36(1):188-99. PubMed ID: 7706943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production.
    Arad Y; Ramakrishnan R; Ginsberg HN
    J Lipid Res; 1990 Apr; 31(4):567-82. PubMed ID: 2351867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates.
    Forster LF; Stewart G; Bedford D; Stewart JP; Rogers E; Shepherd J; Packard CJ; Caslake MJ
    Atherosclerosis; 2002 Sep; 164(1):129-45. PubMed ID: 12119202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TRL, IDL, and LDL apolipoprotein B-100 and HDL apolipoprotein A-I kinetics as a function of age and menopausal status.
    Matthan NR; Jalbert SM; Lamon-Fava S; Dolnikowski GG; Welty FK; Barrett HR; Schaefer EJ; Lichtenstein AH
    Arterioscler Thromb Vasc Biol; 2005 Aug; 25(8):1691-6. PubMed ID: 15933247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human apolipoprotein (Apo) B-48 and ApoB-100 kinetics with stable isotopes.
    Welty FK; Lichtenstein AH; Barrett PH; Dolnikowski GG; Schaefer EJ
    Arterioscler Thromb Vasc Biol; 1999 Dec; 19(12):2966-74. PubMed ID: 10591677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A familial combined hyperlipidemic kindred with impaired apolipoprotein B catabolism. Kinetics of apolipoprotein B during placebo and pravastatin therapy.
    Aguilar-Salinas CA; Hugh P; Barrett R; Pulai J; Zhu XL; Schonfeld G
    Arterioscler Thromb Vasc Biol; 1997 Jan; 17(1):72-82. PubMed ID: 9012640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VLDL and IDL apolipoprotein B-100 kinetics in familial hypercholesterolemia due to impaired LDL receptor function or to defective apolipoprotein B-100.
    Zulewski H; Ninnis R; Miserez AR; Baumstark MW; Keller U
    J Lipid Res; 1998 Feb; 39(2):380-7. PubMed ID: 9507998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lovastatin therapy in familial dysbetalipoproteinemia: effects on kinetics of apolipoprotein B.
    Vega GL; East C; Grundy SM
    Atherosclerosis; 1988 Mar; 70(1-2):131-43. PubMed ID: 3162680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs.
    Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2589-600. PubMed ID: 9409231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of stigmastanyl-phosphocholine (Ro 16-6532) and lovastatin on lipid and lipoprotein levels and lipoprotein metabolism in the hamster on different diets.
    Himber J; Missano B; Rudling M; Hennes U; Kempen HJ
    J Lipid Res; 1995 Jul; 36(7):1567-85. PubMed ID: 7595080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
    Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
    Endocrinology; 1999 Nov; 140(11):5293-302. PubMed ID: 10537160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.
    Broyles FE; Walden CE; Hunninghake DB; Hill-Williams D; Knopp RH
    Am J Cardiol; 1995 Jul; 76(2):129A-135A. PubMed ID: 7604788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.
    Hogue JC; Lamarche B; Deshaies Y; Tremblay AJ; Bergeron J; Gagné C; Couture P
    Metabolism; 2008 Feb; 57(2):246-54. PubMed ID: 18191056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
    Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
    Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins.
    Lamon-Fava S; Diffenderfer MR; Barrett PH; Buchsbaum A; Nyaku M; Horvath KV; Asztalos BF; Otokozawa S; Ai M; Matthan NR; Lichtenstein AH; Dolnikowski GG; Schaefer EJ
    Arterioscler Thromb Vasc Biol; 2008 Sep; 28(9):1672-8. PubMed ID: 18566298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-dependent effect of rosuvastatin on apolipoprotein B-100 kinetics in the metabolic syndrome.
    Ooi EM; Barrett PH; Chan DC; Nestel PJ; Watts GF
    Atherosclerosis; 2008 Mar; 197(1):139-46. PubMed ID: 17416370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of ezetimibe on the in vivo kinetics of apoB-48 and apoB-100 in men with primary hypercholesterolemia.
    Tremblay AJ; Lamarche B; Cohn JS; Hogue JC; Couture P
    Arterioscler Thromb Vasc Biol; 2006 May; 26(5):1101-6. PubMed ID: 16528005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoprotein A-I, B-100, and B-48 metabolism in subjects with chronic kidney disease, obesity, and the metabolic syndrome.
    Batista MC; Welty FK; Diffenderfer MR; Sarnak MJ; Schaefer EJ; Lamon-Fava S; Asztalos BF; Dolnikowski GG; Brousseau ME; Marsh JB
    Metabolism; 2004 Oct; 53(10):1255-61. PubMed ID: 15375779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes.
    Welty FK; Lichtenstein AH; Barrett PH; Dolnikowski GG; Schaefer EJ
    Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1703-7. PubMed ID: 15242863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.